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ABSTRACT
Background: Extended spectrum β-lactamase (ESBL)-producing bacteria have become recognized 
as a problem in South America. The aim of this study was to evaluate risk factors and mortality rate 
in bacteremia caused by ESBL-producing Klebsiella pneumoniae in a Brazilian hospital. Methods: 
A three-year retrospective cohort study with 104 cases of K. pneumoniae bacteremia (61 ESBL and 
43 non-ESBL). Several clinical and laboratory variables were evaluated. The outcome of interest was 
30-day mortality. The adequate treatment was evaluated according to antibiotic susceptibility. Re-
sults: Multivariable analysis showed that central venous catheter and mechanical ventilation were 
independent risk factors for ESBL. The duration of hospitalization before the bacteremia was not a 
risk factor. Mortality was similar in ESBL and non-ESBL and inadequate therapy was not shown to 
be a risk factor. Conclusion: ESBL-producing Klebsiella bacteremia can occur early, suggesting that 
a carbapenem should be included in the initial empirical therapy for bacteremia in patients under 
mechanical ventilation and/or central venous catheter in our institution.
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INTRODUCTION
Gram-negative rods are the leading cause of 
bloodstream infection in Brazilian hospitals 
with increasing incidence of extended spec-
trum β-lactamase (ESBL)–producing bacteria.1 
Klebsiella pneumoniae is the most important 
ESBL-producing bacteria, and the incidence 
has reached worrisome levels and continues to 
increase in South America.2 
Mortality rate is evidently associated with 
inadequate empirical antibiotic choice for ESBL 
bacteria. Carbapenems are the drugs of choice 
for treatment of ESBL-producing K. pneumoni-
ae (ESBL-KP), but this class of drugs is not al-
ways used as first option in empirical treatment 
for early nosocomial infection in developing 
countries. Inadequate restriction of carbapen-
ems by some infection control programs may 
be associated with increasing mortality.
Considering the problem of inadequate 
treatment and mortality rate among patients 
with ESBL and non-ESBL strains of K. pneu-
moniae bacteremia, this study evaluated risk 
factors for mortality in patients with blood-
stream infection caused by ESBL-KP in a Bra-
zilian hospital with high incidence of this mi-
croorganism.
METHODS
A retrospective cohort was carried out at the 
Hospital Universitário Evangélico de Curitiba, 
a reference center for trauma, burn and renal 
transplant. This center is a 660-bed tertiary-
care hospital in Curitiba, a city located in 
Southern Brazil with 60 intensive care beds.
From January 2006 to January 2009, 884 
positive blood cultures were identified (exclud-
ing coagulase negative Staphylococcus) and 
11.7% were positive for K. pneumoniae. All the 
patients with bacteremia caused by K. pneumo-
niae were included in our study. Patients with 
more than one positive blood culture were in-
cluded only once. Only data associated with 
the first bacteremia and patients older than 12 
years-old were evaluated.
Cultures were collected and processed 
using the BACT/Alert® (bioMérieux, Dur-
ham, USA). Klebsiella species were identified 
using biochemical analysis.3 Susceptibility 
testing was performed by the disk diffusion 
method according to the CLSI guidelines.4
The following variables were evaluated for 
each patient: sex; age; previous hospital admis-
sion within 90 days; admission to the intensive Este é um artigo Open Access sob
 a licença de CC BY-NC-ND
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care unit; length of hospitalization before bacteremia; use of 
mechanical ventilation, central venous line, urinary cath-
eter and surgery during the current hospitalization; un-
derlying conditions such as diabetes mellitus, chronic renal 
failure, heart failure, neoplasm, acute renal failure, trauma 
and previous antibiotic use during current hospitalization. 
Previous infection or colonization with K. pneumoniae was 
evaluated. We assumed that the patients who were not cul-
tured were negative for statistical analyses purposes.
Dynamic variables were included, as heart and respira-
tory rate, temperature, mean arterial pressure and Glasgow 
Coma Scale (GCS) in the day of the bacteremia. The fol-
lowing laboratory results were evaluated on the day of bac-
teremia: hemoglobin level, leukocyte and platelet counts, 
sodium, potassium, creatinine, urea, total billirubin and 
partial pressure of oxygen from arterial blood.
Thirty-day or in-hospital mortality was registered. An-
tibiotic treatment was classified as adequate or inadequate. 
Treatment of each patient was considered adequate if 
K. pneumoniae was susceptible to the antibiotic used dur-
ing bacteremia and treatment was initiated within the first 
48 hours of bacteremia diagnosis. Carbapenem (ertap-
enem, imipenem or meropenem) or polymyxin was con-
sidered the adequate antibiotic for ESBL-KP, when correct 
dose was administered. Tygecycline was not used and the 
hospital strains were not susceptible to aminoglycoside or 
fluoroquinolones during the period analyzed. The treat-
ment for non-ESBL-KP was considered adequate if suscep-
tible in vitro.
Statistical analysis
Patients with ESBL-KP bacteremia were compared with 
those with non-ESBL-KP bacteremia to determine factors 
associated with carbapenem resistance. A second analysis 
was performed comparing patients who died during hospi-
talization with those who survived. Continuous data were 
expressed as mean ± standard deviation (SD) or median 
with ranges. Frequencies were expressed as percentages. 
Dichotomous variables were compared using Chi-square 
and Mann Whitney test was used for continuous variables. 
Significance level was set at 0.05. Variables with p < 0.10 in 
the univariated analysis were included in the multivariable 
analysis. Multivariate analysis was performed using binary 
logistic regression model. Odd ratios (OR) with 95% confi-
dence intervals (95% CI) were calculated for each variable. 
Variables in which 95% CI did not include 1.0 were main-
tained in the final model.
Kaplan–Meier survival estimates were calculated to 
evaluate the role of adequate treatment in the outcome of 
bacteremia caused by ESBL-KP, and the difference was as-
sessed using the log-rank test.
All data were stored using the software Excel (Mi-
crosoft, New York, USA) and statistical analysis was 
performed using the software SPSS 11.5 (SPSS, Chi-
cago, USA). Kaplan–Meier survival estimates were de-
termined with GraphPad Prism 4.0 (GraphPad, La Jolla, 
USA). 
RESULTS
One hundred and four patients were included in this study. 
Sixty-three patients were enrolled as ESBL-KP (60%) and 
41 patients with non-ESBL-KP (40%). The median age of 
all patients included was 43.0 years (range, 12-86) and 43% 
were female. The mean length of hospitalization was 45.87 
± 36.60 days and the mean duration of hospitalization until 
first K. pneumoniae bacteremia was 18.8 ± 17.81 days. Char-
acteristics of the patients and laboratory data are described 
in the Table 1. 
In the univariate analysis, factors associated with ESBL 
included invasive procedures as mechanical ventilation 
(p = 0.007), the use of central venous catheter (p = 0.009), 
and elective surgery (p = 0.023). Other risk factors as-
sociated with ESBL were male sex (p = 0.027), diabetes 
mellitus (p = 0.043), and admission to the intensive care unit 
(p = 0.017). Previous use of fourth generation cephalosporin 
(p = 0.003) was a risk factor as well. Although resistant strains 
were associated to longer stay in the hospital, hospitalization 
length until the bacteremia was not a risk factor for ESBL 
infection (Figure 1). Even though these finding supports the 
association with ESBL infection, only mechanical ventilation 
(p = 0.022) and central venous line (p = 0.017) turned out to 
be independent risk factors for ESBL-KP bacteremia in the 
multivariate analysis. All other investigated risk factors were 
significant only in the univariate analysis.
Global ESBL-KP and non-ESBL-KP mortality rates were 
similar (49.2% vs. 41.9%, p = 0.43). Kaplan–Meier estimates 
of survival were also similar for ESBL-KP and non-ESBL-KP 
infected patients (Figure 2A). There was no independent 
risk factor associated with higher mortality rate at the mul-
tivariate analysis. 
Only 55 patients (52.9%) received adequate treatment 
within 48 hours of bacteremia. Mortality of patients receiv-
ing adequate treatment was 50.9% (28 of 55 patients), and 
40.8% in patients with inadequate antibiotic therapy (20 
of 49 patients). Mortality of Klebsiella bacteremia was not 
attributed to inadequate treatment as demonstrated in the 
Kaplan-Meier curve (Figure 2B). Patients infected by either 
ESBL or non-ESBL strains who received adequate therapy 
had similar mortality rates (p = 0.43). 
DISCUSSION
In our study, 58% of the Klebsiella strains were ESBL-pro-
ducing. Marra et al.5 found similar rate, showing 52% of 
ESBL-KP in another Brazilian hospital. Meropenem Yearly 
Susceptibility Test Information Collection (MYSTIC) study 
described a different panorama in North America, Asia and 
Tuon, Kruger, Terreri, et al.
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Table 1. Clinical and laboratory characteristics of 104 patients with K. pneumoniae bacteremia
Variables ESBL group Non-ESBL group OR p 
  (n = 63) (n = 41) (95% CI) 
Age – yr    
 Mean 38.3 ± 21.7 44.2 ± 25.3  0.79 
 Range [12-85] [12-86]  
Gender – n (%)     
 Male 41 (65) 18 (44) 2.62 (1.16-5.93) 0.027 
 Female 22 (35) 23 (56)  
Coexisting diseases – n (%)     
 Diabetes mellitus 7 (11) 11 (9) 2.24 (0.99-5.07) 0.043 
 Chronic renal failure 4 (10) 6 (21) 0.41 (0.10-1.61) 0.168 
 Heart failure 4 (10) 3 (11) 0.93 (0.19-4.50) 0.613 
 Arterial systemic hypertension 17 (42) 13 (46) 0.85 (0.32-2.25) 0.470 
 Neoplastic diseases 6 (15) 3 (11) 1.47 (0.34-6.45) 0.447 
 Chronic hemodialysis 3 (7) 4 (14) 0.48 (0.10-2.37)  
 Trauma 11 (26) 4 (14) 2.28 (0.64-8.07) 0.160
Days before K. pneumoniae 20.2 ± 17.9 16.7 ± 17.5  0.053
Duration of hospitalization 52.2 ± 39.6 36.0 ± 29.4  0.117
Risk factor – n (%)     
 Intensive care unit 49 (80) 23 (53) 3.55 (1.49-8.48) 0.017 
 Previous admission (< 90 days) 15 (24) 14 (32) 0.63 (0.26-1.50) 0.117 
 Previous K. pneumoniae  
 colonization/infection 28 (46) 11 (20) 2.18 (0.93-5.11) 0.056 
 Acute renal failure 11 (28) 4 (14) 2.28 (0.64-8.07) 0.160 
 Mechanical ventilation 26 (40) 9 (22) 3.08 (1.37-6.96) 0.007 
 Central venous catheter 27 (41) 10 (28) 2.71 (1.21-6.06) 0.009 
 Urinary catheter 30 (75) 15 (53) 2.60 (0.93-729) 0.058 
 Elective surgery 28 (41) 12 (28) 3.11 (1.14-8.53) 0.003
Laboratory findings – mean ± SD     
 Hemoglobin (g/dL) 10.2 ± 2.0 10.5 ± 2.1  0.594 
 Leucocytes (1000x cells/mm3) 17.6 ± 13.0 18.4 ± 28.0  0.856 
 Immature cells (%) 17.0 ± 13.0 19.0 ± 14.9  0.685 
 Platelets (1000x cells/mm3) 176.8 ± 154.2 176.2 ± 120.6  0.151 
 Creatinine (mg/dL) 1.7 ± 1.5 1.6 ± 1.9  0.800 
 Partial oxygen pressure (mmHg) 97.5 ± 39.4 86 ± 28.3  0.328 
 Billirubin (mg/dL) 3.3 ± 4.2 3.8 ± 2.6  0.234 
 Heart rate (max) 119.0 ± 33.6 104.8 ± 40.0  0.300 
 Respiratory rate (max) 27.9 ± 16.6 24.5 ± 10.9  0.915 
 GCS 10.0 ± 4.6 10.3 ± 5.7  0.919
Previous antibiotic use     
 Third generation cephalosporin 13 (21) 3 (7) 3.61 (0.96-13.57) 0.05 
 Fourth generation cephalosporin 22 (35) 4 (9) 5.50 (1.73-17.44) 0.001 
 Vancomycin 12 (19) 9 (20) 0.93 (0.35-2.44) 0.42 
 Carbapenem 18 (29) 7 (16) 2.15 (0.81-5.73) 0.13
ESBL-Klebsiella bacteremia
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previous use of cefepime was a risk factor for ESBL in our 
study. This risk factor had not been confirmed previously.12,13 
In our hospital, cefepime is commonly used for the treat-
ment of severe community pneumonia at the emergency 
room. The use of cefepime is a modifiable risk factor, and 
restriction of cefepime use could be an approach to decrease 
ESBL-KP in our institution. Other risk factors for ESBL 
strains were invasive procedures, which included central ve-
nous line and mechanical ventilation.
Previous studies showed a mortality rate between 
20 and 40% in patients with bacteremia caused by 
K. pneumoniae.14-16 The mortality rate in our study was high, 
when compared to other studies. Although no direct com-
parison to patients from other studies can be made, in our 
study patients were severely ill. The first explanation would 
be a higher proportion of patients with K. pneumoniae 
bacteremia receiving inadequate empirical therapy. None-
theless, despite being elevated the rate of inadequate 
treatment was not associated with mortality of ESBL bac-
teremia patients. Du et al.17 demonstrated that inadequate 
treatment was an isolated risk factor, justifying early and 
empirical use of carbapenems in patients with bacteremia 
in some hospitals. The cost of carbapenem restricts its use in 
developing countries, increasing mortality as demonstrated 
in Nigeria.16 A previous publication of Paterson18 under-
scored that early treatment with carbapenems is particularly 
important in seriously ill patients with nosocomial infec-
tions, mainly those caused by ESBL strains, decreasing the 
mortality rate. However, larger sample size of patients would 
be required to draw more definitive conclusions.
Some caveats must be considered in our study. It is a 
retrospective analysis from an isolated institution with 
particular characteristics, the infection control program 
includes strict restriction of carbapenems, the attributed 
mortality for ESBL-KP was not calculated and some vari-
ables were not included in the analysis, such as APACHE 
score. A clonal study should be performed to determine the 
strain as well as the type of the ESBL bacteria. One of 
the factors associated with ESBL-KP bacteremia was previ-
ous use of cefepime. This could be due to bias as ESBL-KP 
were compared with non-ESBL producing KP and this group 
of patients very probably did not use cefepime (as cefepime 
would have eradicated the susceptible microorganism).
CONCLUSION 
In conclusion, mortality due to K. pneumoniae infection is 
high and more than 50% of patients were under inadequate 
treatment in the ESBL group, justifying the use of carbap-
enem as first choice in patients admitted to centers with 
high incidence of ESBL-producing species. We believe that a 
change in the empirical treatment is necessary, mainly in pa-
tients with sepsis during hospitalization, which can decrease 
the global mortality of patients infected by ESBL-KP. The 
Europe (Northern and Southern) in the SMART study with 
only 17% ESBL-producers Klebsiella spp.6 Data from the 
MYSTIC study from South America showed 52% of resist-
ance to cefepime, which can be a surrogate for ESBL strains.7 
Use of beta-lactam antibiotics containing an oxyimino 
group (cefuroxime, ceftriaxone, cefotaxime, ceftazidime, or 
aztreonam) are risk factors for ESBL-KP.8-11 Nevertheless, 
Figure 1: Hospital lengh and bacteremia caused by ESBL 
strains and non-ESBL strains.
Figure 2: Mortality curve from patients with K. pneumoniae 
(ESBL vs. non-ESBL) (A); and patients under correct or wrong 
therapy for K. pneumoniae bacteremia (B). 
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time to use this group of drugs should not be guided by hos-
pitalization length, because we could not correlate increased 
resistance with duration of hospitalization. Our institution 
will change the carbapenem restriction and assess the long 
term benefits of this approach in the mortality of patients 
with ESBL infection as well as the effect on resistance profile. 
We believe that this approach must be implemented in oth-
er institutions according to local epidemiology. Although 
ESBL constituted < 10% of all bacteremia in our hospital, we 
can not neglect the 50% inadequate therapy for this group 
of bacteria.
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